Please login to the form below
Farxiga
This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.
AZ raises full-year guidance after completing Alexion acquisition in Q2
Farxiga. Meanwhile, Q2 net profit was down by 25% from the previous year, coming in at $550m for the quarter.
Latest news
-
AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients
Also, of importance, we learned that [Farxiga]’s well-established safety profile was consistent in DARE-19,” he added. ... Initially, Farxiga was approved in 2014 to improve glycemic control in adults with type 2 diabetes when administered alongside
-
AZ forecasts growth in 2021 after revenues surge in Q4
That growth was led by an increase in revenue for AZ’s heart failure treatment Farxiga (dapagliflozin), which saw a 27% increase in 2020 to $1.96bn.
-
Bayer’s finerenone scores FDA priority review for chronic kidney disease
In September 202 0, AstraZeneca announced that its SGLT2 inhibitor Farxiga (dapagliflozin) plus standard of care reduced the risk of cardiovascular or renal death and worsening of renal function by 39% ... Earlier this year, Farxiga also won a priority
-
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
This includes Novartis’ Entresto (sacubitril/valsartan) and AstraZeneca’s Farxiga (dapagliflozin) which have been steadily adding indications to their labels since initial approval.
-
AZ’s Farxiga cuts risk of death in chronic kidney disease
AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual ... The results from this study are not likely to be
AZ’s Farxiga has no significant benefit for hospitalised COVID-19 patients
Bayer’s finerenone scores FDA priority review for chronic kidney disease
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
AZ’s Farxiga cuts risk of death in chronic kidney disease
More from news
Approximately 14 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Diabetes therapy Farxiga (dapagliflozin) has the potential to go where no other drug in the SGLT2 inhibitor class has gone before as it secures approval for heart failure in both diabetic
-
China: AstraZeneca’s new engine for growth and innovation
One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
-
Transforming times at AstraZeneca
and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.
20 for 2020 – Five pharma companies to watch
China: AstraZeneca’s new engine for growth and innovation
Transforming times at AstraZeneca
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- WHO to test three more potential COVID-19 treatments
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA green lights study of phage-based drug for resistant infections
- First oral antiviral drug for COVID-19 reviewed by Health Canada
PMHub
integrated medhealth communication
imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
